XBiotech Inc. (XBIT)
$2.16-5.68%Close
BUYRECOVERY · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $66M
- Beta
- 0.80
- P/E (TTM)
- -1.46
- Short % float
- 1.70%
- Days to cover
- 10.0
- SI change
- -5.5%
- 1W
- +0.00%
- 1M
- -0.46%
- vs SPY 1W
- +0.14%
- vs SPY 1M
- -2.97%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 9
- VALUE
- 28
- GROWTH
- 39
- GARP
- 0
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-19.0%
REV YoY-
ROE-31.6%
EPS YoY-
ROA-33.8%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.46
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.51
P/FCF-
EV/EBITDA1.05
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO33.15
ND/EBITDA-
BETA0.80
Company news
FAQ
- What is LOPJLB’s current signal on XBIT?
- LOPJLB’s latest quantitative signal on XBiotech Inc. (XBIT) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is XBIT in?
- XBiotech Inc. (XBIT) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does XBiotech Inc. (XBIT) do?
- XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad…